The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
hERG toxicity assessment: Useful guidelines for drug design
Open accessAbstract
All along the drug development process, one of the most frequent adverse side effects, leading to the failure of drugs, is the cardiac arrhythmias. Such failure is mostly related to the capacity of the drug to inhibit the human ether-à-go-go-related gene (hERG) cardiac potassium channel. The early identification of hERG inhibition properties of biological active compounds has focused most of attention over the years. In order to prevent the cardiac side effects, a great number of in silico, in vitro and in vivo assays have been performed. The main goal of these studies is to understand the reasons of these effects, and then to give information or instructions to scientists involved in drug development to avoid the cardiac side effects. To evaluate anticipated cardiovascular effects, early evaluation of hERG toxicity has been strongly recommended for instance by the regulatory agencies such as U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA). Thus, following an initial screening of a collection of compounds to find hits, a great number of pharmacomodulation studies on the novel identified chemical series need to be performed including activity evaluation towards hERG. We provide in this concise review clear guidelines, based on described examples, illustrating successful optimization process to avoid hERG interactions as cases studies and to spur scientists to develop safe drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cryo-electron microscopy of vitrified specimens
Dubochet, J., Adrian, M., Chang, J.-J., Homo, J.-C., Lepault, J., McDowall, A. W., & Schultz, P. (1988) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583500004297 · Cited by 2,389
X-ray structure of a voltage-dependent K+ channel
Jiang, Y., Lee, A., Chen, J., Ruta, V., Cadene, M., Chait, B. T., & MacKinnon, R. (2003) · Nature · doi:10.1038/nature01580 · Cited by 1,797
Crystal structure and mechanism of a calcium-gated potassium channel
Jiang, Y., Lee, A., Chen, J., Cadene, M., Chait, B. T., & MacKinnon, R. (2002) · Nature · doi:10.1038/417515a · Cited by 1,332
A structural basis for drug-induced long QT syndrome
Mitcheson, J. S., Chen, J., Lin, M., Culberson, C., & Sanguinetti, M. C. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.210244497 · Cited by 944
Lipophilicity in drug discovery
Waring, M. J. (2010) · Expert Opinion on Drug Discovery · doi:10.1517/17460441003605098 · Cited by 873
ADMET-score – a comprehensive scoring function for evaluation of chemical drug-likeness
Guan, L., Yang, H., Cai, Y., Sun, L., Di, P., Li, W., Liu, G., & Tang, Y. (2019) · MedChemComm · doi:10.1039/c8md00472b · Cited by 712
Drug discovery and development: Role of basic biological research
Mohs, R. C., & Greig, N. H. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.10.005 · Cited by 673
Managing the drug discovery/development interface
Kennedy, T. (1997) · Drug Discovery Today · doi:10.1016/s1359-6446(97)01099-4 · Cited by 522
Farid, R., Day, T., Friesner, R. A., & Pearlstein, R. A. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.12.032 · Cited by 502
Cryo-EM Structure of the Open Human Ether-à-go-go -Related K + Channel hERG
Wang, W., & MacKinnon, R. (2017) · Cell · doi:10.1016/j.cell.2017.03.048 · Cited by 500
Medicinal Chemistry of hERG Optimizations: Highlights and Hang-Ups
Jamieson, C., Moir, E. M., Rankovic, Z., & Wishart, G. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060379l · Cited by 423
Why Drugs Fail - A Study on Side Effects in New Chemical Entities
Schuster, D., Laggner, C., & Langer, T. (2005) · Current Pharmaceutical Design · doi:10.2174/138161205774414510 · Cited by 417
Cavalli, A., Poluzzi, E., De Ponti, F., & Recanatini, M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm0208875 · Cited by 382
Wrobleski, S. T., Moslin, R., Lin, S., Zhang, Y., Spergel, S., Kempson, J., Tokarski, J. S., Strnad, J., Zupa-Fernandez, A., Cheng, L., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00444 · Cited by 382
Molecular obesity, potency and other addictions in drug discovery
Hann, M. M. (2011) · MedChemComm · doi:10.1039/c1md00017a · Cited by 363
Cardiotoxicity of antimalarial drugs
White, N. J. (2007) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(07)70187-1 · Cited by 349
Fermini, B., Hancox, J. C., Abi-Gerges, N., Bridgland-Taylor, M., Chaudhary, K. W., Colatsky, T., Correll, K., Crumb, W., Damiano, B., Erdemli, G., et al. (2016) · SLAS Discovery · doi:10.1177/1087057115594589 · Cited by 302
Recanatini, M., Poluzzi, E., Masetti, M., Cavalli, A., & De Ponti, F. (2005) · Medicinal Research Reviews · doi:10.1002/med.20019 · Cited by 285
Predictive in silico modeling for hERG channel blockers
Aronov, A. M. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03278-7 · Cited by 267
Ekins, S., Crumb, W. J., Sarazan, R. D., Wikel, J. H., & Wrighton, S. A. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.2.427 · Cited by 260
Pearlstein, R. A., Vaz, R. J., Kang, J., Chen, X.-L., Preobrazhenskaya, M., Shchekotikhin, A. E., Korolev, A. M., Lysenkova, L. N., Miroshnikova, O. V., Hendrix, J., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00196-3 · Cited by 222
Mullard, A. (2019) · Nature Reviews Drug Discovery · doi:10.1038/d41573-019-00014-x · Cited by 212
In-Silico ADME Models: A General Assessment of their Utility in Drug Discovery Applications
Paul Gleeson, M., Hersey, A., & Hannongbua, S. (2011) · Current Topics in Medicinal Chemistry · doi:10.2174/156802611794480927 · Cited by 196
Hughes, B. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2813 · Cited by 191
Development of Safe Drugs: The hERG Challenge
Kalyaanamoorthy, S., & Barakat, K. H. (2018) · Medicinal Research Reviews · doi:10.1002/med.21445 · Cited by 174
Role of hERG potassium channel assays in drug development
Priest, B. T., Bell, I. M., & García, M. I. (2008) · Channels · doi:10.4161/chan.2.2.6004 · Cited by 170
Biftu, T., Sinha-Roy, R., Chen, P., Qian, X., Feng, D., Kuethe, J. T., Scapin, G., Gao, Y. D., Yan, Y., Krueger, D., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401992e · Cited by 166
A quantitative assessment of hERG liability as a function of lipophilicity
Waring, M. J., & Johnstone, C. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.12.061 · Cited by 159
Matched Molecular Pair Analysis in drug discovery
Dossetter, A. G., Griffen, E., & Leach, A. G. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.03.003 · Cited by 156
Kim, D., Wang, L., Hale, J. J., Lynch, C. L., Budhu, R. J., MacCoss, M., Mills, S. G., Malkowitz, L., Gould, S. L., DeMartino, J. A., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.02.030 · Cited by 152
Wood, C., Williams, C., & Waldron, G. J. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03064-8 · Cited by 143
Micro-Electrode Arrays in Cardiac Safety Pharmacology
Meyer, T. S., Boven, K.-H., nther, E. G., & Fejtl, M. (2004) · Drug Safety · doi:10.2165/00002018-200427110-00002 · Cited by 134
Pinard, E., Alanine, A. I., Alberati, D., Bender, M., Borroni, E., Bourdeaux, P., Brom, V., Burner, S., Fischer, H., Hainzl, D., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100210p · Cited by 134
Papadatos, G., Alkarouri, M., Gillet, V. J., Willett, P., Kadirkamanathan, V., Luscombe, C. N., Bravi, G., Richmond, N. J., Pickett, S. D., Hussain, J., et al. (2010) · Journal of Chemical Information and Modeling · doi:10.1021/ci100258p · Cited by 126
The multiple modes of action of propafenone
Dukes, I. D., & Williams, E. M. V. (1984) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a061621 · Cited by 125
Ion Channels as Drug Targets in Central Nervous System Disorders
Waszkielewicz, A. M., Gunia‐Krzyżak, A., Szkaradek, N., Słoczyńska, K., Krupinska, S., & Marona, H. (2013) · Current Medicinal Chemistry · doi:10.2174/0929867311320100005 · Cited by 116
Polak, S., Wiśniowska, B., & Brandys, J. (2008) · Journal of Applied Toxicology · doi:10.1002/jat.1395 · Cited by 107
New potential binding determinant for hERG channel inhibitors
Saxena, P., Zangerl‐Plessl, E., Linder, T., Windisch, A., Hohaus, A., Timin, E., Hering, S., & Stary‐Weinzinger, A. (2016) · Scientific Reports · doi:10.1038/srep24182 · Cited by 100
Yang, Z., Barrow, J. C., Shipe, W. D., Schlegel, K.-A. S., Shu, Y., Yang, F., Lindsley, C. W., Rittle, K. E., Bock, M. G., Hartman, G. D., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800830n · Cited by 98
Goldberg, F. W., Finlay, M. R. V., Ting, A. K. T., Beattie, D., Lamont, G. M., Fallan, C., Wrigley, G. L., Schimpl, M., Howard, M. R., Williamson, B., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01684 · Cited by 98
Cardiovascular and smooth muscle pharmacology in the next decade
Atkinson, J. (2010) · Frontiers in Pharmacology · doi:10.3389/fphar.2010.00001 · Cited by 88
Screening lead compounds for QT interval prolongation
Netzer, R., Ebneth, A., Bischoff, U., & Pongs, O. (2001) · Drug Discovery Today · doi:10.1016/s1359-6446(00)01602-0 · Cited by 87
Bell, I. M., Gallicchio, S. N., Abrams, M. T., Beese, L. S., Beshore, D. C., Bhimnathwala, H., Bogusky, M. J., Buser, C. A., Culberson, J. C., Davide, J. P., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm010531d · Cited by 84
Matched Molecular Pair Analysis: Significance and the Impact of Experimental Uncertainty
Krämer, C., Fuchs, J. E., Whitebread, S., Gedeck, P., & Liedl, K. R. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500317a · Cited by 77
Anti-metastatic Inhibitors of Lysyl Oxidase (LOX): Design and Structure–Activity Relationships
Leung, L. M. H., Niculescu‐Duvaz, D., Smithen, D. A., Lopes, F., Callens, C., McLeary, R., Saturno, G., Davies, L. C., Aljarah, M., Brown, M., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00335 · Cited by 77
Natural products modulating the hERG channel: heartaches and hope
Kratz, J. M., Grienke, U., Scheel, O., Mann, S. A., & Rollinger, J. M. (2017) · Natural Product Reports · doi:10.1039/c7np00014f · Cited by 76
Optimization of the in Vitro Cardiac Safety of Hydroxamate-Based Histone Deacetylase Inhibitors
Shultz, M. D., Cao, X., Chen, C. H., Cho, Y. S., Davis, N. R., Eckman, J., Fan, J., Fekete, A., Firestone, B., Flynn, J., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200388e · Cited by 67
Du‐Cuny, L., Chen, L., & Zhang, S. (2011) · Journal of Chemical Information and Modeling · doi:10.1021/ci200271d · Cited by 61
Construction of an integrated database for hERG blocking small molecules
Sato, T., Yuki, H., Ogura, K., & Honma, T. (2018) · PLoS ONE · doi:10.1371/journal.pone.0199348 · Cited by 59
Human ether-à-go-go-related potassium channel: exploring SAR to improve drug design
Cavalluzzi, M. M., Imbrici, P., Gualdani, R., Stefanachi, A., Mangiatordi, G. F., Lentini, G., & Nicolotti, O. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.11.005 · Cited by 58
Cathepsin C Inhibitors: Property Optimization and Identification of a Clinical Candidate
Furber, M., Tiden, A. K., Gardiner, P., Mete, A., Ford, R., Millichip, I., Stein, L., Mather, A. N., Kinchin, E. C., Luckhurst, C. A., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401705g · Cited by 56
Czodrowski, P. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci400308z · Cited by 53
Epstein, O. I., Bryan, M. C., Cheng, A. C., Derakhchan, K., Dineen, T. A., Hickman, D., Hua, Z., Human, J. B., Kreiman, C. R., Marx, I. E., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm501266w · Cited by 48
Garbaccio, R. M., Fraley, M. E., Tasber, E. S., Olson, C. M., Hoffman, W. F., Arrington, K. L., Torrent, M., Buser, C. A., Walsh, E. S., Hamilton, K., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.12.094 · Cited by 47
Crystal structure of PI3Kgamma with a dihydropurinone inhibitor (compound 4)
Petersen, J., Oster, L., Schimpl, M., Goldberg, F. W., Finlay, M. R. V., Ting, A. K. T., Beattie, D., Lamont, G. M., Fallan, C., Wrigley, G. L., et al. (2019) · Worldwide Protein Data Bank · doi:10.2210/pdb6t3b/pdb · Cited by 46
Cid, J. M., Tresadern, G., Vega, J. A., de Lucas, A. I., del Cerro, A., Matesanz, E., Linares, M. L., Molina, A. G., Iturrino, L., Pérez‐Benito, L., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00913 · Cited by 43
Stereoselective Inhibition of the hERG1 Potassium Channel
Grilo, L. S., Carrupt, P., & Abriel, H. (2010) · Frontiers in Pharmacology · doi:10.3389/fphar.2010.00137 · Cited by 42
Predictive in silico Off-Target Profiling in Drug Discovery
Schmidt, F., Matter, H., Heßler, G., & Czich, A. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.13.202 · Cited by 41
van der Stelt, M., Cals, J., Broeders-Josten, S., Cottney, J. E., van der Doelen, A. A., Hermkens, M., de Kimpe, V., King, A. W. T., Klomp, J. P. G., Oosterom, J., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200916p · Cited by 40
Osborne, J. D., Matthews, T. P., McHardy, T., Proisy, N., Cheung, K.-M. J., Lainchbury, M. D., Brown, N., Walton, M. I., Eve, P. D., Boxall, K. J., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01938 · Cited by 39
Accelerated drug discovery by rapid candidate drug identification
Bergström, F., & Lindmark, B. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.03.026 · Cited by 36
Cho, Y. S., Whitehead, L., Li, J., Chen, C. H. ‐., Jiang, L., Vögtle, M., Francotte, E. R., Richert, P., Wagner, T., Traebert, M., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100007m · Cited by 35
Haile, P. A., Casillas, L., Bury, M. J., Mehlmann, J. F., Singhaus, R. R., Charnley, A. K., Hughes, T. V., DeMartino, M. P., Wang, G. Z., Romano, J. J., et al. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00344 · Cited by 34
Phenotypic Screens Targeting Neurodegenerative Diseases
Zhang, M., Luo, G., Zhou, Y., Wang, S., & Zhong, Z. (2013) · SLAS DISCOVERY · doi:10.1177/1087057113499777 · Cited by 32
Meredith, E. L., Mainolfi, N., Poor, S. H., Qiu, Y., Miranda, K., Powers, J. J., Liu, D., Ma, F., Solovay, C., Rao, C., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01227 · Cited by 32
Matralis, A. N., Malik, A., Penzo, M., Moreno, I., Almela, M. J., Camino, I., Crespo, B., Saadeddin, A., Ghidelli‐Disse, S., Rueda, L., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01099 · Cited by 30
Cumming, J. G., Tucker, H., Oldfield, J., Fielding, C., Highton, A. J., Faull, A. W., Wild, M. J., Brown, D. S., Wells, S. L., & Shaw, J. S. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.12.117 · Cited by 29
Hirose, H., Yamasaki, T., Ogino, M., Mizojiri, R., Yumiko, T.-O., Yashiro, H., Muraki, Y., Nakano, Y., Sugama, J., Hata, A., et al. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.06.007 · Cited by 28
Development of Dual Chitinase Inhibitors as Potential New Treatment for Respiratory System Diseases
Mazur, M., Dymek, B., Koralewski, R., Sklepkiewicz, P. L., Olejniczak, S., Mazurkiewicz, M., Piotrowicz, M., Salamon, M., Jędrzejczak, K., Zagożdżon, A., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00681 · Cited by 26
A fingerprint pair analysis of hERG inhibition data
Springer, C., & Sokolnicki, K. L. (2013) · Chemistry Central Journal · doi:10.1186/1752-153x-7-167 · Cited by 23
Hanser, T., Steinmetz, F. P., Plante, J. P., Rippmann, F., & Krier, M. (2019) · Journal of Cheminformatics · doi:10.1186/s13321-019-0334-y · Cited by 22
Dynamics of hERG Closure Allow Novel Insights into hERG Blocking by Small Molecules
Schmidtke, P., Ciantar, M., Théret, I., & Ducrot, P. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci5001373 · Cited by 18
Berglund, S., Egner, B. J., Gradén, H., Gradén, J., Morgan, D. G. A., Inghardt, T., & Giordanetto, F. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.05.066 · Cited by 13
1H-Pyrrolo[3,2-b]pyridine GluN2B-Selective Negative Allosteric Modulators
Chrovian, C. C., Soyode-Johnson, A., Wall, J. L., Rech, J. C., Schoellerman, J., Lord, B., Coe, K. J., Carruthers, N. I., Nguyen, L., Jiang, X., et al. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00542 · Cited by 13
Optimization of tetrahydronaphthalene inhibitors of Raf with selectivity over hERG
Huang, S.-C., Adhikari, S., Afroze, R., Brewer, K., Calderwood, E. F., Chouitar, J., England, D. B., Fisher, C., Galvin, K. M., Gaulin, J., et al. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.01.049 · Cited by 10
Mutant p53 rescued by aggregation inhibitor
Flemming, A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.13 · Cited by 8
Ogiyama, T., Inoue, M., Honda, S., Yamada, H., Watanabe, T., Gotoh, T., Kiso, T., Koakutsu, A., Kakimoto, S., & Shishikura, J. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.10.020 · Cited by 5
Metadata
- Authors
- Garrido, A., Lepailleur, A., Mignani, S. M., Dallemagne, P., & Rochais, C.
- Venue
- European Journal of Medicinal Chemistry
- Publisher
- Elsevier BV
- Published
- 2020-06
- Volume
- 195
- Pages
- 112290
- ISSN
- 0223-5234 (ISSN-L)
- OpenAlex
- W3014691264
- Cited by
- 344
- References
- 77
- FWCI
- 17.18
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.